| The following article features coverage from the 2018 Genitourinary Cancers Symposium. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Complete responses may be observed in about 8% of patients with metastatic urothelial carcinoma receiving nivolumab monotherapy regardless of PD-L1 status, according to research being presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California.1
Continue Reading
Previous data suggested that nivolumab monotherapy may improve outcomes after progression on at least 1 prior platinum therapy. Here researchers present updated results from the phase 1/2 CheckMate 032 study (ClinicalTrials.gov Identifier: NCT01928394).
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation for other reasons; the median age was 65.5 years and two-thirds of patients had received at least 2 prior therapies.
The minimum follow-up was 24 months. Two-thirds of patients discontinued treatment because of disease progression; 14.1% of patients were still receiving treatment when data were locked. The overall response, progression-free survival (PFS), and overall survival (OS) rates were not affected by PD-L1 status.
The objective response rate was 25.6%, the median PFS was 2.8 months, and the median OS was 10 months; the median response duration was not reached. The complete response rate was 8%.
More than one-fourth (28.2%) of patients had a grade 3 to 4 adverse event; one case of grade 5 pneumonitis was noted.
The authors concluded that nivolumab “showed clinically meaningful, durable efficacy with promising long-term survival regardless of PD-L1 expression, and no new toxicity signals with longer-term follow-up.”
Read more of Cancer Therapy Advisor‘s coverage of the 2018 Genitourinary Cancers Symposium by visiting the conference page.
Reference
- Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in metastatic urothelial carcinoma: longer-term efficacy and safety results from the CheckMate 032 study. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA.
